ABSTRACT
I in the thyroid gland, its effective half-life and previous treatment with antithyroid drugs (ATD). Lithium carbonate blocks the release of organic iodine and thyroid hormone from the thyroid gland without affecting thyroidal active iodine uptake. Accordingly, it is a doubt whether the short-term addition of lithium carbonate, before and after RIT, could prevent the short deterioration of hyperthyroidism and improve therapeutic effect in patients with GD. To address this question, we performed a randomized controlled study to evaluate the addition of lithium carbonate to RIT therapy.
SUBJECTS AND METHODS

Study Groups
During the period from October 2010 to July 2012, we enrolled 100 sequential GD patients with RIT treated for the first time in our department. The age of 29 females ranged from 17 to 62 years (mean 37.5 years), and the age of 71 females ranged from 10 to 53 years (mean 29.7 years). Random allocation was taken to averagely 50 patients into two groups: group (A) patients treated with 131 I and group (B) patients treated with 131 I plus lithium carbonate. There were no significant difference between the age of two groups (t = 1.019, p > 0.05). Patients in B group were treated with lithium carbonate half one month before and after 131 I treatment at a dose of 0.5 g per day (2 × 0.25 g). Each patient received a baseline evaluation, including routine tests of blood, urine and stool, liver and renal functions, thyroid ultrasonography and electrocardiogram. Any patient who had liver or renal disease was excluded from the study.
The study was approved by the investigational review boards and human use committees in Fujian Medical University 2 nd Affiliated Hospital.
Laboratory Study
Thyroid weight was estimated by ultrasonography and careful palpation, and no difference was found between the two groups (t = 0. I was more than 370 MBq, two-dose baiting was given at the first dosage of 314.5 MBq and the remains were given after 48 hours. There was no significant difference on the average dose of 131 I between two groups (t = 1.049, p > 0.05). For patients in both groups, radiation absorbed dose rate the front of neck was measured on days 1530 and 45 after the administration of 131 I. Serum creatinine and blood urea nitrogen was measured after 15 d of treatment in B group patients, and free T3, free T4 and TSH were tested before and on days 30, 45, 90, 180 after treatment.
Evaluation
The therapeutic effects of patients were defined during half year visit as follows: 1) Clinical cure. Symptoms and signs of hyperthyroidism totally disappeared after half year visit, with normal rang of serum FT3 and FT4. 2) Improvement. The symptoms alleviated and signs disappeared partially; Serum FT3 and FT4 decreased significantly, but they were still above normal range. 3) Invalid. The symptoms and signs did not ameliorate, even aggravated; Serum FT3 and FT4 did not decrease significantly. 4) Recurrence. The symptoms and signs of hyperthyroidism reappeared, and thyroid hormones rise again after achieving the criteria of clinical cure. 5) Hypothyroidism. The symptoms and signs of hypothyroidism appeared in patients with low thyroid hormones but high TSH.
Statistical Analysis
Data were analyzed using SPSS 16.0 for Windows. Results were presented as means ± SD for normal distribution and median (M) for skewed distribution. The therapeutic effects of two groups were compared by x-square test. ANOVA with post hoc Dunnett's T3 test was used to compare serum thyroid hormones and radiation absorbed dose rate the front of neck between two groups before and after treatment. Differences between the two groups of the same period in serum thyroid hormones were evaluated by t test. All p values < 0.05 (two-tailed) were considered to be significant.
RESULTS
Our study, after treatment with 31 I plus lithium carbonate, showed that serum urea nitrogen and creatinine were in normal range on days 15. Table 1 showed changes in radiation absorbed dose rate the front of neck in A group and B group. The mean 24 h-RAIU before RIT was 87.2% in A and 89.5% in B group, without significant difference (t = 0.887, p > 0.05) between them. After RIT, radiation absorbed dose rate the front of neck decreased gradually as time went on (F = 17.65, <0.01), all of which were significantly higher in B group than that in A group (F = 98.12, <0.01).
Dosimetry
Thyroid Hormone Levels
Of all different time periods before and after treatment, the mean serum TSH of the two groups were below the normal level without significant difference (F = 1.235, p > 0.05), and serum free T3 and free T4 had significant differences (F = 9.651, F = 22.45, respectively. p < 0.01) ( Table 2) . Neither free T3 nor free T4 values of the pretreated patients in both groups showed any difference (t = 0.987, t = 1.011, respectively, all p > 0.05); but free T3 and free T4 values in different time period after RIT showed significant difference between the two groups (all p < 0.01). We found that free T3 and free T4 values in both groups rose significantly one month after treatment (Dunnett-t = 5.23, 10.14; 5.12, 9.98; all p < 0.01), then decreased to the normal ranges. In pretreated patients, both free T3 and free T4 values experienced decrease on days 45 
The Efficiency of Treatment
As expected, cure of hyperthyroidism was achieved in 36 of the 50 patients (72%) treated with I plus lithium had a higher probability of being cured than patients treated with 131 I alone, although the two groups did not significantly differ at the end of the study (p > 0.05). In addition, 11 (22%) treated with 10 (20%) treated with 131 I plus lithium had improving hyperthyroidism. Table 3 showed the details.
DISCUSSION
With radiation damage of thyroid follicle, temporary thyrotoxic symptoms and signs are the most common thyroid dysfunction in patients after receiving treatment due to the released thyroid hormones. The results showed that serum thyroid hormones elevated significantly after treatment of 131 I, accounting for the symptoms above. In addition, we also found that one month later, serum thyroid hormones were elevated much lower in patients treated with lithium carbonate as an adjunct to 131 I than that in patients treated with 131 I alone, indicating the effectiveness of lithium carbonate in blocking the release of lithium carbonate from thyroid gland.
Lithium carbonate blocks the release of organic iodine I, there was no significant difference between the two groups on cure rate, improvement rate and inefficiency. Whether it illustrated that lithium carbonate did not produce a final outcome of 131 I therapy on hyperthyroidism? However, the results could not draw an appropriate conclusion based on the half-year study, and one or more years' follow-up is needed.
Results which were available from previous study showed that RIT was a well-established method to treat Graves' hyperthyroidism, the efficacy of which could be affected by several factors, such as the short persistence of radioiodine in the thyroid gland, effective half-life, previous treatment with antithyroid drugs (ATD), goiter volume and RAIU. The condition of patients will be transiently aggravated in the presence of radioactive thyroiditis, as well as ATD withdrawal before 131 I administration [1] [2] [3] [4] . Based on the available studies, with no significant alleviation or aggravation, or worrying about the short-term deterioration of thyrotoxicosis after 131 I treatment, patients failed to discharge ATD administration before RIT treatment. Due to its radio resistance, pretreatment of PTU could diminish the therapeutic effectiveness or produce a higher failure rate of RIT. Based on the available literature, discontinuation of ATD for at least 4 days (propylthiouracil for 2 weeks) is required prior to RIT [1, [5] [6] [7] [8] [9] . Fundamental and clinical investigations demonstrated that lithium carbonate, antipsychotic drug, could rapidly resist hyperthyroidism and elevate RAIU, and prolong effective half-time of iodine in thyroid gland. However, side effects of lithium therapy on central nervous system and renal, as well as the effectiveness of ATD administration, stemmed from its no regular application in clinical [5, [10] [11] [12] . The present study showed that there were no abnormal results of biochemical test in patients after 15-d treatment by 131 I, indicating that shortterm use of lithium carbonate was harmless on renal organs.
In summary, lithium carbonate could prolong effective half-life of 131 I, and avoid the increase of serum free thyroid hormones one month after 131 I treatment to potentiate the control of thyrotoxia. We suggest that for patients withdrawing of ATD and patients with short effective half-time, as well as those intolerant or invalid, the short-term addition of lithium to 131 I allows for a better control of thyrotoxia and the completeness of treatment. The information of lithium on enhancing half-year cure rate is limited.
